Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity

Hematol Oncol. 2020 Apr;38(2):204-206. doi: 10.1002/hon.2700. Epub 2020 Jan 27.
No abstract available

Keywords: antibodies response; multiple myeloma; rasburicase; tumor lysis syndrome.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / drug therapy*
  • Acute Kidney Injury / enzymology
  • Acute Kidney Injury / immunology
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Autoantibodies / blood
  • Autoantibodies / immunology*
  • Bortezomib / administration & dosage
  • Dexamethasone / administration & dosage
  • Female
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Prognosis
  • Thalidomide / administration & dosage
  • Urate Oxidase / administration & dosage
  • Urate Oxidase / antagonists & inhibitors
  • Urate Oxidase / immunology*
  • Uric Acid / blood

Substances

  • Autoantibodies
  • rasburicase
  • Uric Acid
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Urate Oxidase